CollPlant Biotechnologies Ltd
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About CollPlant Biotechnologies
Orthopedic, Prosthetic & Surgical Appliances & Supplies, SIC 3842
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine company focused on medical aesthetics and the 3D bioprinting of tissues and organs. The company develops products based on recombinant human collagen (rhCollagen) produced in genetically engineered tobacco plants using proprietary technology. These offerings address indications in tissue repair and aesthetic medicine, encompassing bioinks, dermal and soft tissue fillers, and 3D-bioprinted tissues such as breast implants. CollPlant collaborates with pharmaceutical companies, including Allergan, an AbbVie company, and serves physicians, patients, third-party payors, and the broader medical community.
The company maintains its principal executive offices and research and development facilities in Rehovot, Israel, located within the Weizmann Science Park. CollPlant conducts operations through corporate entities comprising subsidiaries in Israel and the United States. Its development and commercialization initiatives address global healthcare and aesthetics markets through strategic partnerships, distributors, and resellers worldwide.
Summary of the business section of CollPlant Biotechnologies's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CollPlant Biotechnologies Ltd
- Founded
- 2004
- Headquarters
- Rehovot, L3
- Address
- 4 Oppenheimer St., 11th Floor 74140
- Phone
- 972-73-232-5600
- Website
- collplant.com
- Employees
- 39, Dec 31, 2025
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Incorporated in
- L3
- Fiscal year ends
- December 31
- Auditor
- Kost Forer Gabbay & Kasierer, Tel-Aviv, Israel
Stock & identifiers
- Ticker
- CLGN
- Exchange
- Nasdaq
- Shares outstanding
- 13M, Dec 31, 2025
- Filer category
- Non-accelerated filer
- Stock splits
- 1-for-10 reverse, Sep 4, 2026; 1-for-50 reverse, Sep 26, 2019
- SEC CIK
- 1631487
- CUSIP
- M2R51X124
- ISIN
- USM2R51X1246
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Yehiel Tal | Chief Executive Officer, Director | 31,137 |
| Bar Berta Abelis | VP Legal | 206,441 |
| Eran Rotem | Deputy CEO and CFO | 516,372 |
| Bowman Bagley | VP Commercial North America | 25,000 |
| Jasmine Seror | VP Product Development | 45,000 |
| Philippe Bensimon | VP Regulations and QA | 2,000 |
| Oren Fahimipoor | VP Operations | 30,000 |
| Hugh M. Evans | Director | 325,554 |
| Elan Penn | Director | 7,500 |
| Alisa Lask | Director | 10,000 |
| Avraham Havron | Director | 10,000 |
Employees
Headcount reported in annual reports
“As of March 15, 2026, we had 39 employees, including 8 in research and development, 24 in manufacturing and 7 in sales, general and administrative positions.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 6, 2019 | Name change | Name changed from CollPlant Holdings Ltd. to CollPlant Biotechnologies Ltd. |
| Jan 29, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |